{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:44:26Z","timestamp":1786995866168,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006260","name":"Technion Israel Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006260","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.pnpbp.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T20:17:28Z","timestamp":1502741848000},"page":"322-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["ErbB signaling antagonist ameliorates behavioral deficit induced by phencyclidine (PCP) in mice, without affecting metabolic syndrome markers"],"prefix":"10.1016","volume":"82","author":[{"given":"Hagar","family":"Tadmor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idit","family":"Golani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravid","family":"Doron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Shamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.08.010_bb0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0269881107067097","article-title":"Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat","volume":"21","author":"Abdul-Monim","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroscience.2009.03.022","article-title":"In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons","volume":"161","author":"Abe","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0015","doi-asserted-by":"crossref","first-page":"13118","DOI":"10.1073\/pnas.1201011109","article-title":"Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors","volume":"109","author":"Andersson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0020","series-title":"Metabolic Syndrome in People With Schizophrenia: A Review","first-page":"15","author":"Article","year":"2009"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0278-5846(01)00159-2","article-title":"Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents","volume":"25","author":"Ashe","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0030","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1523\/JNEUROSCI.2021-14.2014","article-title":"Genetic labeling reveals novel cellular targets of schizophrenia susceptibility gene: distribution of GABA and non-GABA ErbB4-positive cells in adult mouse brain","volume":"34","author":"Bean","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/neuro.08.002.2009","article-title":"Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL\/6J mice","volume":"3","author":"Brigman","year":"2009","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajp.2014.08.002","article-title":"Antipsychotic treatment of schizophrenia: an update","volume":"11","author":"Bruijnzeel","year":"2014","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.brainresbull.2010.07.012","article-title":"The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits","volume":"83","author":"Buonanno","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0050","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1523\/JNEUROSCI.1815-08.2008","article-title":"Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components","volume":"28","author":"Chen","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0055","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.biopsych.2011.08.002","article-title":"ErbB4 localization to interneurons: clearer insights into schizophrenia pathology","volume":"70","author":"Cooper","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/oxfordjournals.schbul.a007038","article-title":"The stress cascade and schizophrenia: etiology and onset","volume":"29","author":"Corcoran","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10715769800300171","article-title":"Antioxidant properties of clozapine and related neuroleptics","volume":"29","author":"Dalla Libera","year":"1998","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0070","article-title":"Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation","author":"Deakin","year":"2011","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.physbeh.2004.01.013","article-title":"Behaviour in the elevated plus-maze predicts coping after subchronic mild stress in mice","volume":"81","author":"Ducottet","year":"2004","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/mol.107.041236","article-title":"Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors","volume":"73","author":"Emanuel","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0085","doi-asserted-by":"crossref","first-page":"pyu114","DOI":"10.1093\/ijnp\/pyu114","article-title":"Neuregulin 1 prevents phencyclidine-induced behavioral impairments and disruptions to GABAergic signaling in mice","volume":"18","author":"Engel","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/mf.2007.29.4.1075358","article-title":"Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis","volume":"29","author":"Enomoto","year":"2007","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","article-title":"Meta-analysis of oxidative stress in schizophrenia","volume":"74","author":"Flatow","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.mp.4001081","article-title":"Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients","volume":"7","author":"Futamura","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.mp.4001138","article-title":"Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development","volume":"8","author":"Futamura","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0110","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.pnpbp.2005.11.009","article-title":"Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine","volume":"30","author":"Gama","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0115","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.euroneuro.2014.09.011","article-title":"Disruption of the ErbB signaling in adolescence increases striatal dopamine levels and affects learning and hedonic-like behavior in the adult mouse","volume":"24","author":"Golani","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0120","doi-asserted-by":"crossref","first-page":"723184","DOI":"10.1155\/2011\/723184","article-title":"GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia","volume":"2011","author":"Gonzalez-Burgos","year":"2011","journal-title":"Neural Plast."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000070012","article-title":"Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients","volume":"47","author":"Gross","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neuroscience.2012.12.017","article-title":"Stress and neurodevelopmental processes in the emergence of psychosis","volume":"249","author":"Holtzman","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0135","first-page":"107","article-title":"Neuregulin 1\/ErbB4 enhances synchronized oscillations of prefrontal cortex neurons via inhibitory synapses","volume":"261C","author":"Hou","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III - the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0150","first-page":"1","article-title":"Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia","author":"Kato","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0155","doi-asserted-by":"crossref","first-page":"e14185","DOI":"10.1371\/journal.pone.0014185","article-title":"Phenotypic characterization of transgenic mice overexpressing neuregulin-1","volume":"5","author":"Kato","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pbb.2016.12.006","article-title":"Effects of withdrawal from repeated phencyclidine administration on behavioural function and brain arginine metabolism in rats","volume":"153","author":"Knox","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0165","first-page":"148","article-title":"Atypical antipsychotic therapy and hyperlipidemia: a review","volume":"6","author":"Koro","year":"2005","journal-title":"Essent. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbr.2017.01.044","article-title":"Trans-generation enrichment of clozapine-responsiveness trait in mice using a subchronic hypo-glutamatergic model of schizophrenia: a preliminary study","volume":"323","author":"Krivoy","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0175","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1073\/pnas.0805722105","article-title":"Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0180","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1073\/pnas.0602002103","article-title":"Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5\u2032 SNPs associated with the disease","volume":"103","author":"Law","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0190","first-page":"8","article-title":"Metabolic changes associated with antipsychotic use","volume":"6","author":"Lieberman","year":"2004","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0195","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0200","article-title":"Prefrontal cortical neuregulin-ErbB modulation of inhibitory control in rats","volume":"1\u20137","author":"Loos","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0205","first-page":"1","article-title":"Effects of antipsychotic drugs on serum biochemical tests","volume":"3","author":"Makeen","year":"2017","journal-title":"Pyrex J. Biomed. Res."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuron.2014.06.007","article-title":"Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases","volume":"83","author":"Mei","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0215","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia","volume":"9","author":"Mei","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tics.2011.11.017","article-title":"Developing treatments for impaired cognition in schizophrenia","volume":"16","author":"Minzenberg","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0225","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1254\/jphs.10099FP","article-title":"Antipsychotic potential of quinazoline ErbB1 inhibitors in a schizophrenia model established with neonatal hippocampal lesioning","volume":"114","author":"Mizuno","year":"2010","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0230","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/tp.2013.29","article-title":"ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions","volume":"3","author":"Mizuno","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0235","doi-asserted-by":"crossref","first-page":"e115225","DOI":"10.1371\/journal.pone.0115225","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse","volume":"9","author":"Morgan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0240","doi-asserted-by":"crossref","first-page":"e27337","DOI":"10.1371\/journal.pone.0027337","article-title":"Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta)","volume":"6","author":"Neddens","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0245","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4161\/cib.2.3.7825","article-title":"Neuregulin links dopaminergic and glutamatergic neurotransmission to control hippocampal synaptic plasticity","volume":"2","author":"Neddens","year":"2009","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0250","first-page":"S170","article-title":"Metabolic syndrome and mental illness","volume":"13","author":"Newcomer","year":"2007","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0255","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neuroscience.2007.03.051","article-title":"Phenotypic characterization of spatial cognition and social behavior in mice with \u201cknockout\u201d of the schizophrenia risk gene neuregulin 1","volume":"147","author":"O'Tuathaigh","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0265","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbr.2009.02.007","article-title":"Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801","volume":"204","author":"Seillier","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0270","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.1899-11.2012","article-title":"The importance of the NRG-1\/ErbB4 pathway for synaptic plasticity and behaviors associated with psychiatric disorders","author":"Shamir","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12888-014-0225-8","article-title":"Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study","volume":"14","author":"Sicras-Mainar","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajmg.b.30275","article-title":"The involvement of ErbB4 with schizophrenia: association and expression studies","volume":"141B","author":"Silberberg","year":"2006","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0285","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nrn2851","article-title":"Behavioural phenotyping assays for mouse models of autism","volume":"11","author":"Silverman","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2017.01.055","article-title":"Behavioral characterization of blocking the ErbB signaling during adolescent and adulthood in reward-liking (preference) and reward-related learning","volume":"326","author":"Tadmor","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0295","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/oxfordjournals.schbul.a007139","article-title":"Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms","volume":"30","author":"Thompson","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0300","article-title":"Down-regulation of neuregulin1\/ErbB4 signaling in the hippocampus is critical for learning and memory","author":"Tian","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0305","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/schbul\/sbn101","article-title":"Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction","volume":"34","author":"Van Winkel","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0310","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0149-7634(05)80194-0","article-title":"Chronic mild stress-induced anhedonia: a realistic animal model of depression","volume":"16","author":"Willner","year":"1992","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0315","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.neuron.2007.04.009","article-title":"Neuregulin-1 enhances depolarization-induced GABA release","volume":"54","author":"Woo","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0320","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.neuron.2013.03.028","article-title":"Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1","volume":"78","author":"Yin","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0325","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"First do no harm. A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"Young","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0330","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2004.08.066","article-title":"Supranigral injection of neuregulin1-beta induces striatal dopamine overflow","volume":"1028","author":"Yurek","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0335","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00213-003-1553-4","article-title":"Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains","volume":"171","author":"Zarate","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.08.010_bb0340","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.pnpbp.2009.03.021","article-title":"Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans","volume":"33","author":"Zheng","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617303810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617303810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T02:48:44Z","timestamp":1548816524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617303810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":68,"alternative-id":["S0278584617303810"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.08.010","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ErbB signaling antagonist ameliorates behavioral deficit induced by phencyclidine (PCP) in mice, without affecting metabolic syndrome markers","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}